ClinicalTrials.gg
Sign In

Cholangitis, Sclerosing clinical trials

The registry lists 149 studies for Cholangitis, Sclerosing across more than 10 countries. 39 are recruiting or about to start. 110 of them are mainly about Cholangitis, Sclerosing (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29.

Get an email when these change. Save the Cholangitis, Sclerosing studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
63
Recruiting
30
Status unknown
16
Terminated
13
Active, not recruiting
10
Not yet recruiting
9

Phase

Phase 2
51
Phase 1
25
Phase 3
17
Early Phase 1
3
Phase 4
1

Where

United States
74
United Kingdom
21
Canada
19
France
17
Germany
14
Italy
14

Who runs them

Mayo Clinic (13) · Gilead Sciences (7) · Assistance Publique - Hôpitaux de Paris (6) · Brigham and Women's Hospital (5) · Stanford University (4) · Perspectum (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · University of Birmingham (3)

What is being tested here

Drugs under test in Cholangitis, Sclerosing studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Vancomycin5212
Elifibranor112
Nor-ursodeoxycholic acid122
Fenofibrate102
Acetylcysteine101
Thioctic Acid101
Nicotinamide-beta-riboside101
Metformin101
Nemolizumab101
Upadacitinib101

Coming up

5phase 3 studies under way
9studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger. 9 (30%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 9 (30%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
106 (20%)6 (20%)
1829 (97%)29 (97%)
3027 (90%)27 (90%)
4027 (90%)27 (90%)
5026 (87%)26 (87%)
6526 (87%)26 (87%)
7522 (73%)22 (73%)
8515 (50%)15 (50%)

Across all 149 studies, recruiting or not: 45% stop at 75 or younger and 13% at 65; 20% take children; 0% are for women only and 1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cholangitis, Sclerosing studies take

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 237 mo21–62 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 149. Browse all 149 → or search them.